AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program

Avrobio Inc. (AVRO) PT Lowered to $6 at Mizuho Securities

January 5, 2022 5:28 PM EST

Mizuho Securities analyst Uy Ear lowered the price target on Avrobio Inc. (NASDAQ: AVRO) to $6.00 (from $28.00) while maintaining a Buy rating.

The analyst commented, "The new clinical data from the Fabry program is disappointing. We update our model to exclude our sales and... More

AVROBIO's (AVRO) Focus Shift is Disappointing, But Logical, Outlook is Cautions - Stifel

January 4, 2022 10:37 AM EST

Stifel analyst Dae Gon Ha maintains a "Hold" rating on shares of AVROBIO Inc. (NASDAQ: AVRO), following news that company is shifting its portfolio... More

AVROBIO Inc. (AVRO) Halted, News Pending

January 4, 2022 6:55 AM EST

AVROBIO Inc. (NASDAQ: AVRO) Halted, News Pending

... More